Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 48INDUSTRY 22NIH 6FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1

Interventions

pembrolizumab 2apalutamide 2abiraterone 2Testosterone 2Radiosurgery 2Leuprolide 2Golytely 2Exercise 2Cryotherapy 2Abiraterone Acetate 2zanubrutinib 1venetoclax 1stenoparib 1relugolix 1olaparib 1nilutamide 1leucoselect phytosome 1ibrutinib 1histrelin 1enzalutamide 1copanlisib 1capivasertib 1bicalutamide 1avelumab 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1acalabrutinib 1Waiting Lists 1Triptorelin Pamoate 1Temozolomide 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × avelumab × 1 year × Clear all
NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡